See the DrugPatentWatch profile for Abilify
Abilify Maintena Availability in China
Abilify Maintena is not currently approved or available in China [1]. The drug is an injectable, long-acting formulation of aripiprazole, used for the treatment of schizophrenia and bipolar disorder [2].
Why Isn't Abilify Maintena Available in China?
Regulatory approval processes in China differ from those in other major markets. Pharmaceutical companies must submit extensive data to the National Medical Products Administration (NMPA) for review, a process that can be lengthy [3]. The specific reasons for Abilify Maintena's absence from the Chinese market are not publicly detailed but likely involve the regulatory submission and approval pathway [1].
What Are the Treatment Options for Schizophrenia and Bipolar Disorder in China?
For patients in China with schizophrenia and bipolar disorder, various oral antipsychotic medications are available. Aripiprazole, in its oral form (Abilify), is approved and marketed in China [4]. Other oral antipsychotics, including both typical and atypical agents, are also accessible [5]. The landscape of injectable long-acting antipsychotics in China is evolving, with approvals for some agents occurring over time [6].
When Might Abilify Maintena Become Available in China?
There is no publicly announced timeline for the potential approval or launch of Abilify Maintena in China. Such introductions depend on Otsuka Pharmaceutical, the drug's developer, initiating and completing the necessary regulatory processes with the NMPA [1][3].
How Does Oral Aripiprazole Compare to Injectable Formulations?
Oral aripiprazole, like Abilify Maintena, works by modulating dopamine and serotonin receptors in the brain [2]. The primary difference lies in the route of administration and pharmacokinetic profile. Oral formulations require daily dosing, while long-acting injectables like Abilify Maintena are administered typically once a month or every few months, offering sustained drug levels and potentially improving treatment adherence for some patients [2][7].
Who Develops Abilify Maintena?
Abilify Maintena was developed by Otsuka Pharmaceutical [2].
What Are the Risks Associated with Long-Acting Injectable Antipsychotics?
As with any antipsychotic medication, long-acting injectables carry potential risks. These can include extrapyramidal symptoms (movement disorders), metabolic changes (weight gain, increased blood sugar, cholesterol), sedation, and other side effects related to dopamine and serotonin modulation [7]. Specific risks associated with Abilify Maintena include injection site reactions [2]. Careful patient selection and monitoring are crucial for managing these risks.
Sources:
[1] https://www. Otsuka.com/en/rd/pipeline/
[2] https://www.abilifyMaintena.com/
[3] https://www.nmpa.gov.cn/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201399/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631695/
[6] https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30102-1/fulltext
[7] https://www.rxlist.com/abilify_Maintena-drug.htm